Semaglutide, another GLP-1 receptor agonist, has demonstrated encouraging results in decreasing the body weight and enhancing the quality of life in individuals with obesity who are diagnosed with HFpEF. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.